WO2002044713A2 - Dispositif a flux traversant pour incubation et /ou hybridation bidimensionnelle sur supports solides - Google Patents

Dispositif a flux traversant pour incubation et /ou hybridation bidimensionnelle sur supports solides Download PDF

Info

Publication number
WO2002044713A2
WO2002044713A2 PCT/EP2001/014222 EP0114222W WO0244713A2 WO 2002044713 A2 WO2002044713 A2 WO 2002044713A2 EP 0114222 W EP0114222 W EP 0114222W WO 0244713 A2 WO0244713 A2 WO 0244713A2
Authority
WO
WIPO (PCT)
Prior art keywords
incubation
solid support
test fluid
fluid
reservoir
Prior art date
Application number
PCT/EP2001/014222
Other languages
English (en)
Other versions
WO2002044713A3 (fr
Inventor
Fredericus Bernardus Josephus Maria Thunnissen
F. Nijpels
Original Assignee
Dot Diagnostics B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dot Diagnostics B.V. filed Critical Dot Diagnostics B.V.
Priority to AU2002220747A priority Critical patent/AU2002220747A1/en
Publication of WO2002044713A2 publication Critical patent/WO2002044713A2/fr
Publication of WO2002044713A3 publication Critical patent/WO2002044713A3/fr

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L7/00—Heating or cooling apparatus; Heat insulating devices
    • B01L7/52—Heating or cooling apparatus; Heat insulating devices with provision for submitting samples to a predetermined sequence of different temperatures, e.g. for treating nucleic acid samples
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F31/00—Mixers with shaking, oscillating, or vibrating mechanisms
    • B01F31/29—Mixing by periodically deforming flexible tubular members through which the material is flowing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F31/00—Mixers with shaking, oscillating, or vibrating mechanisms
    • B01F31/65—Mixers with shaking, oscillating, or vibrating mechanisms the materials to be mixed being directly submitted to a pulsating movement, e.g. by means of an oscillating piston or air column
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F33/00—Other mixers; Mixing plants; Combinations of mixers
    • B01F33/30—Micromixers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0809—Geometry, shape and general structure rectangular shaped
    • B01L2300/0819—Microarrays; Biochips
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0809—Geometry, shape and general structure rectangular shaped
    • B01L2300/0822—Slides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00—Moving or stopping fluids
    • B01L2400/04—Moving fluids with specific forces or mechanical means
    • B01L2400/0475—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00—Moving or stopping fluids
    • B01L2400/04—Moving fluids with specific forces or mechanical means
    • B01L2400/0475—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure
    • B01L2400/0487—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure fluid pressure, pneumatics

Definitions

  • the present invention is in the field of molecular biology and immuno- histochemistry diagnostics, and relates in particular to an improved method of hybridisation on flat solid supports.
  • the method is useful, for example, in the early detection of lung and colon cancer and rapid immunohistochemistry diagnosis in pathology.
  • Cancer is the second overall leading cause of death, after ischemic heart disease, in the United States and Western Europe and despite recent advances in its treatment, there is, for most cancer types, no miracle cure on the horizon. Cancer causes approximately 25 % of all deaths. The incidence continues to rise, probably reflecting the increasing average age of the population. The key to survival is early diagnosis and treatment.
  • Lung cancer has a high incidence and mortality.
  • Early detection programs with conventional methods such as X-ray and sputum cytology have failed to improve mortality.
  • Lung carcinomas are now considered a genetic disease. Many regions in the genome have been thought to contain candidate genes related to the development of lung cancer.
  • K-ras Kirsten ras
  • the capture probe bears a biotin residue and the detection probe digoxigenin.
  • the PCR product hybrids are captured in streptavidin-coated microtiter plates and detected with labeled anti-digoxigenin antibody. For the detection of known point mutations this procedure was extended by using after the capture step the ligation of a mutation-specific capture probe with adjacent detection probe (APoint-EXACCTs).
  • Point-EXACCT Essential in the Point-EXACCT technique is that only molecules will be detected by this format which have been hybridized with two probes and subsequently ligated, resulting in a very high degree of specificity.
  • Point-EXACCT requires considerably less time and effort as compared to other techniques used for the detection of known point mutations. The method can be easily automated, permitting rapid screening of tissue banks with multiple probes to individual base substitutions, deletions or additions.
  • DNA of one mutated cell can be detected in a DNA background of 15,000 wild type cells.
  • This surprising finding may to a large extent be due to careful moving of the hybridisation fluid across the solid support. This procedure looks in fact like the roling of the waves over the sand on the beach, and takes care of frequent mixing of molecules to be bound with the substrate on the solid support.
  • Point mutations in the K-ras oncogene are one of the most common genetic alterations involved in various types of human cancer. In lung cancer, K-ras mutations occur predominantly in codon 12. The frequency of those alterations varies within different histological subtypes. K-ras point mutations are found in approximately 15-56% of the adenocarcinomas and to a lesser extent in other types of non-small cell lung carcinomas (NSCLC). See Somers V.A.M.C, Thesis ibid., and references mentioned therein. In conclusion, the Point-EXACCT has been designed for analysis of single base substitutions, where the exact place of said substutions in the nucleotide sequence of the gene to be analyzed is known beforehand. Validation of the method for the detection of known point mutations in a large group of patients with NSCLC has confirmed its high sensitivity. Importantly, with this technique a relatively low amount of target cells is required before a signal is obtained.
  • the microarray technique allows large scale nucleic acid analysis, but require a large amount of target cells, since the detection mechanism is based on hybridization. Hence there is a need for optimization.
  • the hybridisation is improved low target samples may be examined with greater efficiency i.e. lower concentrations in shorter time.
  • the microscope slide is attached to an incubation chamber and the test fluid is present in a thin layer between chamber walls and glass surface.
  • the advantage of the incubation chamber is that the amount of testfluid necessary is much less than for the horizontally incubated slides.
  • the disadvantage of both procedures is that the fluid is not moved across the slide. During incubation diffusion and binding to target takes place. Binding to target is only a matter of a fraction of a second. Therefore, diffusion time is the important parameter determining the efficiency of the incubation.
  • the total thickness of the fluid column above the epitopes in the incubation chamber can be reduced to around 80 microns, the antibodies present at a longer distance in the other two directions can take quite a while before they are diffused to the epitopes.
  • incubation time varies about 30- 60 minutes. It is conceivable that not all antibodies in the test fluid are used for binding to their target. Thus incubation of antibodies may be improved if diffusion time is reduced.
  • the present invention provides both an improvement of the static two- dimensional hybridisation procedure of nucleic acids on solid supports, for example as used in microarrays, and an improvement of the incubation procedure of antibodies to epitopes on solid supports, for example as used in immunohistochemistry, in immunocyto- chemistry and ELISAs.
  • the first device comprises the following parts (see Figures 1-4): a. a solid support comprising a target for binding; b. a support holder i) comprising the solid support as one of the walls including an incubation space, ii) two reservoirs one on each side of the incubation space where the first one allows test fluid to be entered into the incubation space, and the second one allowing collection of the test fluid; c. means for providing pressure, for example a pump, allowing transport of the test fluid from one reservoir to the other; d. a control system for moving the fluid from one reservoir along the incubation chamber to the other reservoir and back, allowing repeated exposure of test fluid components to the component present on the solid support.
  • the solid support comprises microscope slides containing nucleic acids as targets for hybridisation to other nucleic acids or binding to proteins suitable for microarray analysis.
  • the solid support comprises microscope slides with proteins as targets for antibodies, other proteins or nucleic acids, suitable for microarray analysis.
  • the solid support comprises microscope slides with histologic sections or cytologic material suitable for immunohistochemistry or microscope slides.
  • a flow through device is provided for rapid immunohistochemistry of a single or a few microscopic slides.
  • the two approaches for dynamic two dimensional hybridisation are combined into one assembly.
  • This assembly conveniently comprises a pump as well as a rotatable disc for moving the test fluid.
  • a flow through device is provided which is suitable for carrying out the hybridisation and/or incubation methods in an automatic fashion with a plurality of support holders, suitable for analysis of multiple supports.
  • the reservoir may be very small having hardly any reservoir function left.
  • the rotatable disc space may be optionally designed such that hardly any fluid will occupy the disc area.
  • Figure 2 depicts a possible vertical option where the solid support is attached to the support holder, leaving variable spaces between surface area of solid support and support holder. Note the reservoirs on both sides of the incubation space.
  • Figure 3 depicts also the vertical option but now with front view and possible place for pressure regulating channels and fluid inflow (pipetting spot).
  • Optional are sensors for detecting the fluid level.
  • Figure 4 depicts a horizontal option of the flow through system with similar features as in Figure 3.
  • Figure 5 depicts schematic front and side views of the holder with a totatable disc in the wall of the holder opposite to the solid support.
  • the arrow points to the cylinder where rotating force can be applied.
  • Figure 6 depicts front and side view of the holder with two totatable discs in the wall of the holder opposite to the solid support.
  • Figure 7 depicts the front and side view of the holder with rotatable disc against the wall of the holder opposite the solid support.
  • the disc is rotated e.g. by magnetic forces created by the device outside/on top of the support holder.
  • the present invention provides a significant improvement of the hybridisation of nucleic acids and incubation of antibodies by reducing the diffusion time. This is obtained by a flow through system.
  • the target on the solid support consists of a solid part with attached i.e. immobilized thereon one or more different kinds of molecules, such as nucleic acids, proteins, whole cells, sections of cells or tissues.
  • incubation chamber and “hybridisation chamber”, as used herein, are synonyms and are meant to indicate the three dimensional space above the target present on the solid support, where the solid support is an integral part of the incubation and/or hybridisation chamber.
  • microarray or “chip” technique or technology, as used herein, are synonyms and are meant to indicate analysis of a plurality of small spots of nucleic acids distributed on a small surface area to facilitate large scale nucleic acid analysis enabling the simultaneous analysis of thousands of DNA and/or RNA sequences.
  • the terms are likewise applicable to the analysis of peptides or proteins in a similar way.
  • incubation fluid is meant to indicate the fluid containing the substrate to be bound on the solid support.
  • test fluid is meant to indicate the volume of any fluid component necessary for the experiment/ test to be carried out with the flow through system.
  • the terms “immunohistochemistry” and “immunocytochemistry”, as used herein, are meant as synonyms, indicating the binding of antibodies to parts of tissues or cells present on the solid support. It has now surprisingly been found that compared to the static hybridisation system the hybridisation time can be dramatically reduced in the devices for flow through dynamic hybridisation.
  • the test fluid In one device the test fluid is transported from one reservoir to the other and vice versa ( Figures 1-4).
  • a rotatable disc is part of one of the walls of the holder ( Figures 5-6). This rotating disc takes care of transport of test fluid. In either way the test fluid repeatedly passes along the incubation space with binding target.
  • the dynamic flow procedure reduces the distance of diffusion by repeated short exposures to the target on the solid support.
  • the binding time of the molecules is the restricting factor which is only a matter of a split second.
  • the incubation time for each individual step can be reduced from 30-60 minutes to 15 minutes, preferably 10 or even more preferably 5 minutes or less.
  • the dynamic flow through system consists of a holder for the solid support.
  • the flow through system has an integrated device where two different approaches for fluid transport may be combined or one of both approaches.
  • a simple device has the following parts: i) a place where the solid supports fits in and is an integral part of one of the walls of the incubation chambers, ii) a place for input of test fluid, iii) two reservoirs, one on each side of the incubation chamber, iv) a pump related to one incubation chamber, v) sensors close to the inlet outlet side of incubation chamber, vi) output for overflow / waste of fluids.
  • Still another device combines the two approaches: thus fluid transport is performed by the combination of pressure changes and by rotatable disc(s).
  • a vertical slide holder comprising a small fluid-containing incubation >chamber where the slide is in vertical position in the holder.
  • One of the broad vertical walls of the incubation chamber consists of the solid support with the microarrays (3x1 inches, about 5x2.5 cm).
  • the distance between solid support wall of the incubation chamber and the opposite parallel wall may vary from several hundred microns to one tenth of a micron. The minimal distance is dependent of the size of the objects on the solid support. A distance of 80 microns is sufficient for arrays of nucleic acids, proteins, individual cells and tissue sections. But a distance of 1 or 0,1 micron, which is not working for cells and most tissue sections, is sufficient for analysis of proteins and nucleic acids.
  • Test fluid can be added on top of the upper wedge shaped and wider part of the incubation chamber and the incubation space is filled with test fluid by capillary and gravity force. Excess fluid on the upper level will in due time flow through the incubation space by gravity. The incubation space will remain filled with fluid due to the capillary force in a static fashion.
  • the invention in effect is the possibility of two dimensional dynamic incubation, which is achieved by pressure on the level of one of the reservoirs (e.g 1), containing excess test fluid. The pressure will speed up the passage of fluid from that reservoir along the incubation chamber to the other reservoir. The sensor detects signs of fluid level passage and is used for the stopping of the overpressure. The other reservoir now contains the excess fluid. Reduction of pressure (creating underpressure) on reservoir 1 leads to transport of the fluid back along the incubation chamber to reservoir 1. This procedure can be repeated untill no improvement in signal detection is achieved.
  • a slide holder contains the slide not in vertical, but in another position, e.g. skewed or horizontal.
  • the invention can be performed without sensor(s), using e.g. visual inspection as a way of controlling the fluid transport.
  • the pressure channels can be located on the other reservoir or alternatively on both reservoirs.
  • the size of the incubation chamber can vary from the complete size of the solid support, preferably the size of a microscope glass slide or more preferably the size of a paraffin embedded tissue block or even smaller i.e. the size of cross section of one or a few tissue biopsies.
  • the minimal size of the reservoir is related to the size of the incubation chamber i.e. a larger incubation chamber requires a larger reservoir.
  • the whole flow trough system can be larger than the size of a microscope slide, for larger supports the size of the flow trough system can be adjusted.
  • the wall of the holder contains two or three rotatable discs.
  • the size of the disc may depend on the size of the binding area on the solid support. For example, in microarray analysis and immunohistochemistry on small biopsie specimen on area of 1x1 cm square or less may be sufficient. Whereas for larger sections the area may be 5x2 cm square or even larger.
  • the surface of the rotatable disc may be flat or have some channels or other irregularities on the surface, facilitating mixing of test fluid and reduction of the diffusion distance.
  • the present invention of dynamic incubation and/or hybridisation has the advantage that at least for most specimen in routine pathology a reduction of the amount of incubation and other fluids can be achieved. This effect may even be more impressive for smaller incubation chambers, leading to lower material costs in the test/ experiment.
  • the concentration can be reduced of primary antibodies in immunohistochemistry, since a higher chance of binding may be present due to repeated exposure from the components to be bound.
  • Another important aspect of the invention may be that for samples with a low amount of binding targets in a mixture of other (non-binding) components the chance of binding is dramatically increased.
  • the dynamic incubation not only results in reduction of material costs as mentioned above, but also improves the efficiency low target specimen to a large extent. This is useful e.g. in the field of research for early detection.
  • the device may be used for immuno linked assays other than immunohistochemistry or immunocytochemistry well known to a person skilled in the art.
  • the temperature may be raised as part of optimisation of the hybridisation or incubation conditions.
  • the dynamic flow through system is designed to examine the binding efficiency during flow with conventional fluorescence microscopy and other modes, such as laser scanning microscopy, which will be evident to a person skilled in the art.
  • the detection mode after hybridisation/ incubation on the solid support may vary but the invention can be suitably carried out with absorption microscopy and other modes, such as fluoresence and laser scanning microscopy, which will be evident to a person skilled in the art.
  • the label selected for detection may vary depending on the purpose. As indicated above, this may be a label for fluorescence or chemiluminescence optical systems. Other detection systems may be adapted to the purpose, e.g. IR microscopy, atomic force microscopy, electrical conductance, image plate transfer, and interference microscopy (e.g. Jamin-Lebedief). Such variations which are entirely clear to the man skilled in the art, are all encompassed within the scope of the present invention.
  • Another embodiment of the invention is an instrument having the parallel setup of an array of flow through systems. This allows several solid supports to be analysed at the same time. This system can be automated.
  • the new two dimensional flow through system has the advantage of more efficient hybridisation and/or incubation due to a reduction of diffusion time and test fluids compared to present two dimensional systems, leading to reduction of test time, material costs, better results with low target specimen.
  • microorganisms e.g. for clinical and food applications, such as human papilloma virus, legionella, tuberculosis, etc.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Clinical Laboratory Science (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des dispositifs à flux traversant pour incubation et/ou hybridation sur des supports solides. Un premier dispositif selon l'invention se compose comme suit: (a) support solide avec cible pour liaison ; (b) porte-support sur lequel (i) le support solide constitue l'une des parois matérialisant un espace d'incubation et qui comporte (ii) deux réservoirs situés de part et d'autre de l'espace d'incubation dont la fonction est, pour l'un, de permettre au liquide d'essai de pénétrer dans l'espace d'incubation, et pour l'autre de recueillir le liquide d'essai ; (c) dispositif générateur de pression pour le transfert du liquide d'essai d'un réservoir à l'autre ; (d) système de commande permettant d'acheminer le liquide d'un réservoir via la chambre d'incubation à l'autre réservoir et inversement, ce qui garantit une exposition répétée des composants du liquide d'essai aux composants présents sur le support solide. Un second dispositif selon l'invention se compose comme suit : (a) support solide renfermant une cible pour liaison ; (b) paroi du porte-support faisant face au support solide, dont une partie se compose d'un ou de plusieurs disques rotatifs ; (c) système mécanique réglant la rotation des disques ; (d) dispositif commandant le débit d'entrée du liquide d'essai et la rotation des disques. L'invention concerne également des ensembles dans lesquels sont combinés deux ou plus des dispositifs ci-dessus.
PCT/EP2001/014222 2000-11-30 2001-11-30 Dispositif a flux traversant pour incubation et /ou hybridation bidimensionnelle sur supports solides WO2002044713A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002220747A AU2002220747A1 (en) 2000-11-30 2001-11-30 Flow through device for two dimensional incubation and/or hybridization on solid supports

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00204277 2000-11-30
NL00204277.8 2000-11-30

Publications (2)

Publication Number Publication Date
WO2002044713A2 true WO2002044713A2 (fr) 2002-06-06
WO2002044713A3 WO2002044713A3 (fr) 2002-09-19

Family

ID=8172365

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/014222 WO2002044713A2 (fr) 2000-11-30 2001-11-30 Dispositif a flux traversant pour incubation et /ou hybridation bidimensionnelle sur supports solides

Country Status (2)

Country Link
AU (1) AU2002220747A1 (fr)
WO (1) WO2002044713A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6913931B2 (en) 2002-10-03 2005-07-05 3M Innovative Properties Company Devices, methods and systems for low volume microarray processing

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4726889A (en) * 1986-02-04 1988-02-23 Oncor, Inc. Process and apparatus for conducting electrophoresis and transfer
US5188963A (en) * 1989-11-17 1993-02-23 Gene Tec Corporation Device for processing biological specimens for analysis of nucleic acids
US5382511A (en) * 1988-08-02 1995-01-17 Gene Tec Corporation Method for studying nucleic acids within immobilized specimens
WO2001054814A2 (fr) * 2000-01-26 2001-08-02 Motorola, Inc. Compositions et procedes de realisation de reactions biologiques

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4726889A (en) * 1986-02-04 1988-02-23 Oncor, Inc. Process and apparatus for conducting electrophoresis and transfer
US5382511A (en) * 1988-08-02 1995-01-17 Gene Tec Corporation Method for studying nucleic acids within immobilized specimens
US5188963A (en) * 1989-11-17 1993-02-23 Gene Tec Corporation Device for processing biological specimens for analysis of nucleic acids
WO2001054814A2 (fr) * 2000-01-26 2001-08-02 Motorola, Inc. Compositions et procedes de realisation de reactions biologiques

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6913931B2 (en) 2002-10-03 2005-07-05 3M Innovative Properties Company Devices, methods and systems for low volume microarray processing

Also Published As

Publication number Publication date
WO2002044713A3 (fr) 2002-09-19
AU2002220747A1 (en) 2002-06-11

Similar Documents

Publication Publication Date Title
US11015227B2 (en) Methods and compositions to generate unique sequence DNA probes, labeling of DNA probes and the use of these probes
US20030157523A1 (en) Cell and tissue arrays and microarrays and methods of use
JP5777269B2 (ja) 元素分析によって実施される遺伝子発現アッセイ
Liotta et al. Molecular profiling of human cancer
AU2009201529B2 (en) Apparatus For Polynucleotide Detection and Quantitation
US20100047790A1 (en) Sample analyser
Serrano et al. Whole genome DNA methylation analysis of human glioblastoma using Illumina BeadArrays
JP2002528097A (ja) 細胞アレイならびに遺伝障害マーカーの検出および使用方法
WO1999044062B1 (fr) Arrangements cellulaires permettant une definition de profil moleculaire rapide
Rodriguez-Mateos et al. FISH and chips: a review of microfluidic platforms for FISH analysis
Rummukainen et al. Amplification of c-myc oncogene by chromogenic and fluorescence in situ hybridization in archival breast cancer tissue array samples
EP1135680A1 (fr) Systeme a haut debit pour l'evaluation de l'utilite clinique de cibles moleculaires dans des echantillons de tissus
JP2004514112A (ja) 個別化した医薬に対するアッセイ法の開発システム
JP2005528118A (ja) 高処理一体化化学および生化学反応のための新規方法
Dillon et al. Rapid, efficient genotyping of clinical tumor samples by laser-capture microdissection/PCR/SSCP
WO2002044713A2 (fr) Dispositif a flux traversant pour incubation et /ou hybridation bidimensionnelle sur supports solides
AU7412900A (en) Improved method for nucleotide detection and devices used therein
Bazan et al. Laser pressure catapulting (LPC): optimization LPC‐system and genotyping of colorectal carcinomas
Pandey et al. Assessment of microsatellite instability in colorectal carcinoma at an Indian center
Mägel et al. Next-generation sequencing analysis of laser-microdissected formalin-fixed and paraffin-embedded (FFPE) tissue specimens
Murakami et al. Microplate-based mRNA analysis
JP2021040555A (ja) 核酸試料の品質評価方法
Reissmann DNA probes in evaluation of monitoring human cancer
Fameli-Pavlakis et al. Tissue Molecular Techniques in Lymphoproliferative Disorders: Contribution to Diagnosis, Prognosis, Therapy and Follow up. Bridging Molecular Pathology with Clinical Practice
Silverberg Bioanalytical development tools

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP